Unterehmen auf Watchlist setzen
Revance Therapeutics
ISIN: US7613301099
WKN: A1XD3D
Über
Unternehmensprofil
Tipp: Investor-Alerts aktivieren
Lassen Sie sich bei neuen Publikationen informieren
Tipp: AI-Factsheet

Corporate News meets AI! 
Analyse der Inhalte und Zusammenfassung

Revance Therapeutics · ISIN: US7613301099 · PR Newswire (ID: 20250109NY92381)
09 Januar 2025 11:45AM

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNC


NEW YORK, Jan. 9, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC).

Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/revance-therapeutics-inc-loss-submission-form-2/?id=121491&from=4

CLASS PERIOD: February 29, 2024 to December 6, 2024

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Revance was in material breach of the Distribution Agreement with Teoxane, which granted Revance "the exclusive right to import, market, promote, sell and distribute Teoxane's line of dermal fillers; (ii) the foregoing subjected the Company to an increased risk of litigation, as well as monetary and reputational harm; (iii) all the foregoing increased the risk that the tender offer would be delayed and/or amended; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

DEADLINE: March 4, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/revance-therapeutics-inc-loss-submission-form-2/?id=121491&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of RVNC during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 4, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm

15 West 38th Street, 12th floor

New York, NY, 10018

Email: dg@securitiesclasslaw.com

Phone: (646) 453-8903

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/the-gross-law-firm-reminds-shareholders-of-a-lead-plaintiff-deadline-of-march-4-2025-in-revance-lawsuit--rvnc-302346566.html

SOURCE The Gross Law Firm

Visuelle Wertentwicklung / Kursverlauf · Revance Therapeutics
Smarte Analyse- und Recherchewerkzeuge finden Sie hier.
This publication was provided by our content partner PR Newswire
PR Newswire
via PR Newswire - Newsfeed
Cision ©2025
PR Newswire
Kontakt:
300 S Riverside Plaza, Chicago, Illinois, USA
+001 (0) 888-776-0942